New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.
### Instruction: What is the sentiment of this news? Please choose an answer from {negative/neutral/positive}
### Input: New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.
### Response: moderately positive